First Week of March 20th Options Trading For PROCEPT BioRobotics (PRCT)

PROCEPT BioRobotics (PRCT) trades at $30.29; selling the $25 put (bid $1.10) would commit purchase at $25 but net an effective cost basis of $23.90, about 17% below current price, with a modeled 79% chance to expire worthless and a 4.40% cash return (27.71% annualized) YieldBoost. Selling a $32.50 covered call (bid $2.00) against existing shares would cap sale at $32.50 for a 13.90% return if called at the March 20 expiration, is ~7% OTM with a 51% chance to expire worthless and a 6.60% (41.58% annualized) YieldBoost; implied volatilities are 74% (put) and 81% (call) versus a 54% trailing 12‑month volatility.

Analysis

Market structure: The immediate winners are option premium sellers and yield-seeking investors willing to be long PRCT at a lower effective cost (cash‑secured $25 put nets $23.90) while losers are pure volatility buyers given IV (74–81%) sits ~20–30 percentage points above realized 54% — premium is rich into March 20. This favors strategies that collect premium (covered calls, put-selling) over naked long delta in the next 30–60 days unless a clear catalyst arrives.

Risk assessment: Tail risks include an adverse FDA/regulatory decision, device recall, or a dilutive capital raise; these are low‑probability but could halve the stock in months (−50%+). In the short term (days–weeks) option theta and IV contraction are largest drivers; medium term (1–3 months) product adoption, reimbursement news or earnings drive direction; long term (quarters) commercial execution and cash runway matter.

Trade implications: Tactical plays include cash‑secured $25 puts (21% assignment probability, 79% expire worthless) sized to desired share exposure, buy‑write into $32.50 calls to lock a 13.9% realized return to 20‑Mar, or defined‑risk put spreads ($25/$20) to collect credit while capping downside. If you expect IV mean reversion, sell premium (size to 1–3% portfolio per trade) and use verticals to limit tail risk.

Contrarian angle: Consensus leans toward collecting premium; what it misses is that IV already prices a >20% event risk — if no regulatory news in 60 days IV should compress to ~55–60%, producing 20–40% realized gains for short‑vol sellers. Conversely, buying long equity ahead of a possible negative catalyst is asymmetric and likely underpriced for downside; price thresholds to reassess: break <$20 or IV spike >120%.

Key Decisions for Investors

• Sell a cash‑secured PRCT Mar20 $25 put (collect $1.10) sized so max assignment equals 1–2% of portfolio; target effective entry $23.90, accept assignment probability ~21%; if assigned, trim to a 1% position and target exit at $32.50 or sooner on +30% gain.
• Establish a buy‑write: buy PRCT at ~$30.29 and sell Mar20 $32.50 calls for $2.00 to lock a 13.9% return to 20‑Mar; position size 1–2% portfolio, roll out only if IV >70% and you deem medium‑term fundamentals intact.
• If shorting volatility, sell a defined‑risk put spread: sell Mar20 $25 / buy Mar20 $20 for a net credit (~<$1.10), max loss $4 per spread; size to limit max loss to 0.5–1% portfolio and take profits if IV compresses to ≤60% or spread value falls by 50%.
• Do not increase outright long equity exposure >3% before material catalysts (earnings/regulatory) in the next 30–90 days; if PRCT falls below $20, re‑evaluate for deep‑value accumulation or pair with long position in a larger med‑tech ETF (e.g., IHI) to hedge idiosyncratic risk.